Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral DL-3-n-butylphthalide for SCA3/MJD
ChiCTR-IIR-17012717Phase 2Recruiting
- Sponsor
- Xiangya Hospital, Central South University
- Start
- Sep 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of butylphthalide in machado-joseph disease (MJD) (2 arms), sponsored by Xiangya Hospital, Central South University. Primary endpoints: SARA score, SCAFI and 1 more. Started Sep 2017; status: recruiting.
02
Drugs
butylphthalide
03
Conditions
machado-joseph disease (MJD)
Beyond the preview
Go deeper on ChiCTR-IIR-17012717.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IIR-17012717.